US approves Astrazeneca lung cancer drug Imfinzi for treatment Business Astrazeneca’s lung cancer drug Imfinzi has been approved for treatment in the US to be used both before and after surgery, just days after the company’s market value hit £200bn for the first time. Imfinzi, which is meant to treat early-stage non-small cell lung cancer alongside chemotherapy, is administered before and after surgery. The approval [...]
Can the UK’s stock market produce another £200bn company? Markets Seismic events or a shift in valuations are likely necessary for more UK stocks to be worth £200bn, analysts have told City A.M., after Astrazeneca became the first company in six years to pass the milestone.
FTSE 100 companies BT, Vodafone and Astrazeneca to report earnings this week Tech Key quarterly earning updates from FTSE 100 companies next week, include Vodafone, BT and Astrazeneca.
‘Nobel prize of engineering’ finalist Sunamp to raise Series B as it mulls public offering July 2, 2024 An innovative battery firm nominated for the "nobel prize of engineering" is set to raise a Series B funding round in a few months with a future IPO becoming an increasingly "realistic proposition", its boss has said.
Google Deepmind among nominees for ‘Nobel Prize of engineering’ June 28, 2024 AI-powered weather forecasting, innovative heat batteries and the rapid manufacturing scale-up of a Covid vaccine are the three cutting edge technologies nominated for an engineering award dubbed "the Nobel Prize of Engineering".
Oxford Biomedica issues new shares to secure a £17m investment June 18, 2024 Cell and gene therapy company Oxford Biomedica has announced a near £17m investment which will see it issue new shares to the London Stock Exchange.
Astrazeneca swallows up Canada-based Fusion Pharmaceuticals in £1.5bn move June 5, 2024 Astrazeneca has completed its $2bn (£1.5bn) acquisition of Canada-based Fusion Pharmaceuticals, in a deal first announced in March.
‘New era of growth’: FTSE 100 giant Astrazeneca aims to double revenue May 21, 2024 London-listed Astrazeneca reported revenue of $45.8bn in 2023 and growth of 19 per cent to $12.7bn in the first quarter of 2024.
Astrazeneca to build huge new cancer drug plant in Singapore May 20, 2024 Astrazeneca has said it will invest $1.5bn (£1.2bn) to build a manufacturing facility in Singapore to produce antibody drug conjugates (ADCs), a next-generation cancer treatment.
Astrazeneca: London-listed pharma giant heralds successful breast cancer drug April 29, 2024 Astrazeneca has found that Enhertu helped patients live longer without their breast cancer getting worse compared to standard chemotherapy.